$Palantir Technologies Inc.(PLTR)$ $Hims & Hers Health Inc.(HIMS)$ πŸ”ΊπŸ…±οΈU⃣L⃣L⃣I⃣S⃣Hβƒ£πŸ”Ί

πŸ’ͺπŸ”₯πŸš€πŸ“ˆπŸ’Š These two companies where the retail investor was ahead of institutions❣️:

$PLTR $HIMS

$HIMS

Shares of Hims & Hers Health (HIMS) sank Thursday 3Oct24 after the Food and Drug Administration (FDA) said Eli Lilly’s (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its list of drugs in short supply. And then πŸ’₯ on Friday 4Oct24 HIMS rocketed πŸš€ $18.67 πŸ”Ί(5.49%)πŸ“ˆβ—οΈ

$PLTR

Short term target $42, long term πŸ”₯πŸ”₯πŸ”₯πŸš€

Source: The Motley Fool

Palantir customers benefit from eye-popping productivity gains, but how much will that help its shareholders?

When it comes to growth potential, Palantir (PLTR 1.96%) attracted increased attention in recent months. The generative AI capabilities of its Artificial Intelligence Platform, better known as AIP, delivered massive productivity gains to customers.

Indeed, some of that benefit should accrue to shareholders. The question is whether that gain is sufficient to deliver a 100-fold gain that might help smaller investors, an amount that could turn a $10,000 investment into $1 million or more. 

Palantir's growth potential

Palantir did a smart thing by marketing AIP through its so-called "boot camps." These forums allow prospective customers to use the platform to solve problems, and given the productivity gains, some customers are going to see massive returns.

One customer claimed to be 10 times more efficient using the AIP platform while using one-third of the resources. Also, Palantir says it closed a seven-figure deal with an unnamed wholesale insurance brokerage just days after demonstrating an automated policy review use case.

Such effects inspire other prospective customers to participate in the boot camps and, likely, sign on as customers if they can leverage the platform to make the said productivity gains themselves.

Financial challenges

Still, investors seeing the triple-digit revenue growth of Nvidia and hoping Palantir will grow as fast may have to temper expectations. In the first six months of 2024, revenue of $1.3 billion rose 24% compared to the first two quarters of 2023. While this represents solid growth for Palantir, it might not be enough for some growth investors.

The profit picture looks better, as Palantir earned $240 million in net income in the first half of 2024 versus the $45 million in the same year-ago period. Still, Palantir has only been profitable since Q4 2022, so the growth rate is likely a virtue of early profitability as much as it is a product of its growth.

Also, its stock price growth has taken Palantir's forward P/E ratio to 103 and the price-to-sales (P/S) ratio to 35. This is expensive by any measure and probably means that the stock has already realized some of the growth needed to make millionaires.

Moreover, according to consensus estimates, analysts forecast 24% revenue growth in 2024 and 21% the following year. While such growth is bullish for Palantir, it may not be enough to support its current valuation.

Furthermore, Palantir's market cap has risen to $82 billion. A 100-fold gain in the stock would take the market cap to $8.2 trillion. This is about 2.3 times the $3.4 trillion market cap of Apple, the current market cap leader. That shows the extent of how much Palantir is going to have to grow to make millionaires out of small investors.

Will Palantir mint millionaires?

Palantir can certainly help small investors become millionaires, but it is not likely the SaaS stock will take them to that point on its own.

Indeed, the productivity gains hold the potential to take Palantir stock much higher over time. So, even if new buyers do not become millionaires, they will likely become significantly wealthier by owning this stock.

However, the revenue growth may not yet reflect the growth potential that AIP has now offered its users. That could turn the short- and medium-term outlook for Palantir negative for a time.

Also, even if time proves the analysts wrong and revenue growth accelerates, the $82 billion size of Palantir will mean its market cap will have to be more than double that of the current record market cap to deliver a 100-fold gain from today's levels. Additionally, investors may question the 35 P/S ratio if that faster revenue growth does not materialize.

Palantir can still emerge as a long-term winner despite those concerns, but at current levels, small investors should temper any "millionaire" expectations.

$BBVA Banco Frances SA(BBAR)$ will be another one. 🎯 $14.50 to $15.00. Institutions don't tend to look south β¬‡οΈπŸ‡¦πŸ‡·.They are skeptical of Latin America and bullish cycles start out of cynicism. Population growth rate is much higher than North America. It's currently an underpenetrated market (developing)!

Source: Yahoo Finance

Banco BBVA (BBAR), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Banco BBVA currently has a Zacks Rank of #1 (Strong Buy). πŸ’ͺπŸ’ͺπŸ’ͺ Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

Happy trading ahead, cheers, BC πŸ€

@Tiger_comments @Daily_Discussion @TigerGPT @TigerPicks @TigerPM @TigerStars @TigerWire

# Billionaire Peter Thiel sells Palantir (PLTR.US) stock again, cashing out more than $1 billion this year

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment(23οΌ‰

  • Top
  • Latest
  • TigerGPT
    Β·10-06
    TOP

    I have analyzed the stocks you mentioned: Palantir Technologies Inc. (PLTR), Hims & Hers Health Inc. (HIMS), and BBVA Banco Frances SA (BBAR). Here are the key findings:

    Hims & Hers Health Inc. (HIMS):

    Support price: $10.37 (USD)  

    Resistance price: $20.27 (USD)  

    Current stock price: $17.66 (USD) (as of October 6th, 2024)  

    Analyst target price estimates: Mean - $21.93, Low - $16.0, High - $30.0  

    Earnings forecast: The company is expected to have a positive EPS and gross income growth in the coming years. Analysts forecast an EPS of $0.22 for 2024 and $0.37 for 2025.  

    Capital flow data: In the past 5 days, there have been mixed inflows and outflows of funds for HIMS.  

    Analyst recommendation: There are multiple recommendations, including buys and holds, suggesting a neutral sentiment on the stock.  

      

    BBVA Banco Frances SA (BBAR):

    Support price: $10.37 (USD)  

    Resistance price: $11.29 (USD)  

    Current stock price: $11.13 (USD) (as of October 6th, 2024)  

    Analyst target price estimates: Mean - $12.97, Low - $7.9, High - $22.0  

    Earnings forecast: The company is expected to have positive EPS and gross income growth in the future. Analysts forecast an EPS of $1.88 for 2024 and $2.17 for 2025.  

    Capital flow data: In the past 5 days, there have been mixed inflows and outflows of funds for BBAR.  

    Analyst recommendation: There are multiple recommendations, including buys, holds, and underperforms, suggesting mixed sentiment on the stock.  

      

    Palantir Technologies Inc. (PLTR):

    Support price: $35.93 (USD)  

    Resistance price: $40.03 (USD)  

    Current stock price: $40.01 (USD) (as of October 6th, 2024)  

    Analyst target price estimates: Mean - $27.38, Low - $9.0, High - $50.0  

    Earnings forecast: The company is expected to have positive EPS and gross income growth in the future. Analysts forecast an EPS of $0.36 for 2024 and $0.43 for 2025.  

    Capital flow data: In the past 5 days, there have been mixed inflows and outflows of funds for PLTR.  

    Analyst recommendation: There are multiple recommendations, including buys, holds, underperforms, and sells, suggesting mixed sentiment on the stock.  

      

    It's important to note that I am providing you with factual information and analyzing the current situation of these stocks. However, investment decisions should not be solely based on this information. It's always recommended to conduct thorough research and consider your risk tolerance before making any investment decisions.

    Please remember that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks carries risks, including the potential loss of principal. Please make independent investment decisions.

    Reply
    Report
    Fold Replies
    • TigerGPTReplying toBarcode:Β 

      You're welcome! If you have any more questions or need further assistance, feel free to ask. Cheers and good luck with your investments! πŸ€

      10-07
      Reply
      Report
    • BarcodeReplying toTigerGPT:Β 
      Thanks TigerGPT, Cheers BC πŸ€
      10-07
      Reply
      Report
    • TigerGPTReplying toBarcode:Β 

      Here are some recent news articles related to Hims & Hers Health Inc. (HIMS):

      Hims & Hers to Replace Vector Group in the S&P SmallCap 600: Hims & Hers Health will replace Vector Group in the S&P SmallCap 600 index starting on October 9th, which has garnered positive attention for the company.

        

      Hims & Hers Stock Soars After Positive Outlook on Weight Loss Product Demand: Truist analyst reports suggest that Hims & Hers' compounded GLP-1 weight loss offering could continue to have strong demand even after the resolution of branded drug shortages.

        

      Please note that these articles are for informational purposes only and do not constitute investment advice. It's important to conduct thorough research and consider your own risk tolerance before making any investment decisions.

      Apologies, but I couldn't find any additional news specifically related to Hims & Hers Health Inc. (HIMS) during the specified time period. For more up-to-date information, you may want to visit the stock quote page or check reliable financial news sources.

      10-07
      Reply
      Report
    View more 1 comments
  • Cool Cat Winston
    Β·10-06
    TOP

    $BBVA Banco Frances SA(BBAR)$ $Palantir Technologies Inc.(PLTR)$ $Hims & Hers Health Inc.(HIMS)$ πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      πŸ‘πŸ‘πŸ‘
      10-06
      Reply
      Report
  • Kiwi Tigress
    Β·10-06
    TOP

    $BBVA Banco Frances SA(BBAR)$ $Palantir Technologies Inc.(PLTR)$ 🌊🌊🌊🌊🌊🌊

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Riding that wave KT! Cheers for the shares, πŸ€
      10-06
      Reply
      Report
  • Great article, would you like to share it?

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Cheers for the shares CCW, πŸ€
      10-07
      Reply
      Report
  • Tui Jude
    Β·10-06

    Great article, would you like to share it?

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Cheers for the double shares TJ, πŸ€
      10-06
      Reply
      Report
    • Barcode:Β 
      Cheers for the double shares Q, πŸ€
      10-06
      Reply
      Report
  • Tui Jude
    Β·10-06

    Great article, would you like to share it?

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Cheers for the shares TJ, πŸ€
      10-06
      Reply
      Report
  • Hen Solo
    Β·10-06

    Great article, would you like to share it?

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Cheers for the shares HS, πŸ€
      10-06
      Reply
      Report
  • Great article, would you like to share it?

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Cheers for the double shares Q, πŸ€
      10-06
      Reply
      Report
    • Barcode:Β 
      Cheers for the shares Q, πŸ€
      10-06
      Reply
      Report
  • Great article, would you like to share it?

    Reply
    Report
    Fold Replies
    • Barcode:Β 
      Cheers for the shares Q, πŸ€
      10-06
      Reply
      Report